Figure 3
From: CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
CDKN2A LOF and survival. Kaplan–Meier curves of patients with CDKN2A wild-type (WT) and loss-of-function (LOF) NSCLC demonstrating (a) PFS for entire cohort, (b) OS for entire cohort, (c) OS for high TMB subset (≥ 10 mutations/megabase), and (d) OS for high PD-L1 subset (≥ 50%).
